Stifel Nicolaus Sticks to Their Buy Rating for Alkermes (ALKS)
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Alkermes (ALKS – Research Report) today and set a price target of $36.00. The ...
Stifel Nicolaus Reaffirms Their Buy Rating on Disc Medicine (IRON)
In a report released today, Benjamin Burnett from Stifel Nicolaus maintained a Buy rating on Disc Medicine (IRON – Research Report), with a ...